By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

APEIRON Biologics AG 

Campus-Vienna-Biocenter 5

Vienna    1030  Austria
Phone: 43-1-865-65-77 Fax: 43-1-865-65-77-800


SEARCH JOBS


Industry
Biotechnology

Segment
Biotechnology





Company News
APEIRON Biologics AG Collaborates With Idis Ltd to Initiate Managed Access Program 9/25/2013 8:29:53 AM
Rentschler Biotechnologie GmbH & Co. Produces APEIRON Biologics AG's Monoclonal Antibody APN311 for Late Stage Clinical Development and Market 8/1/2013 8:10:42 AM
APEIRON Biologics AG Release: Success in Avoiding Radiation Skin Damage for Breast Cancer Patients 3/5/2013 11:33:56 AM
APEIRON Biologics AG Closes Regional License Agreement for Antibody-Based Immunotherapy 1/18/2013 9:31:54 AM
APEIRON Biologics AG Establishes Biotech-Spinoff Attoquant Diagnostics 12/4/2012 11:55:18 AM
APEIRON Biologics AG Initiates Clinical Study to Investigate Prevention of Radiation-Induced Skin Damage in Breast Cancer Patients 2/27/2012 12:10:39 PM
APEIRON Biologics AG Release: Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone 12/19/2011 10:46:41 AM
Evotec AG (EVTG.F) and APEIRON Biologics AG Start Next Project on the Cbl-b Target 10/20/2011 10:44:04 AM
Children's Oncology Group and APEIRON Biologics AG to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301) 9/29/2011 11:16:18 AM
Oncology Alliance: APEIRON Biologics AG, CCRI and SIOGEN Biotech Join Forces Against Neuroblastoma 6/22/2011 9:56:20 AM
12
//-->